US Stock MarketDetailed Quotes
FNCH Finch Therapeutics
- 11.950
- -0.200-1.65%
15min DelayClose Nov 4 13:58 ET
19.19MMarket Cap-1357P/E (TTM)
12.100High11.950Low1.03KVolume12.050Open12.150Pre Close12.30KTurnover0.15%Turnover RatioLossP/E (Static)1.61MShares14.26052wk High1.35P/B8.31MFloat Cap0.80052wk Low--Dividend TTM695.02KShs Float675.000Historical High--Div YieldTTM1.24%Amplitude0.800Historical Low11.985Avg Price1Lot Size
About Finch Therapeutics Company
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Company Profile
SymbolFNCH
Company NameFinch Therapeutics
Listing DateMar 19, 2021
Issue Price17.00
Founded2014
CEOMr. Matthew P. Blischak
MarketPink Market
Employees1
Fiscal Year Ends12-31
Address75 State Street,Suite 100
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02109
Phone1-617-229-6499
Company Executives
- Name
- Position
- Salary
- Matthew P. Blischak
- Chief Executive Officer, President, and Secretary
- --
- Lance Thibault, C.P.A.
- Chief Financial Officer and Principal Accounting Officer
- --
- Susan E. Graf
- Chairman of the Board
- 187.99K
- Chris Shumway
- Independent Director
- 147.59K
- Jeffrey A. Smisek
- Independent Director
- 161.74K
- Domenic Ferrante
- Independent Director
- 146.49K
- Christian Lange
- Independent Director
- 155.99K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data